Recently, covalent inhibitors targeting specific KRAS-G12C mutation have been developed and shown satisfactory preclinical efficacy in KRAS-G12C mutated tumor models (Patricelli et al., 2016; Fell et al., 2018). Here, KRAS is linked to neoplasm.